Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2
Home
Publications
Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2
Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2
Authors:
OA
Olga González Albarrán
Olga González Albarrán
FA
F. Javier Ampudia-Blasco
F. Javier Ampudia-Blasco
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Publisher website
Google Scholar
1 September 2013
journal article
review article
Published by
Elsevier
in
Medicina Clinica
Vol. 141
,
36-43
DOI:
10.1016/s0025-7753(13)70062-9
PMID:
24444523
Abstract
No abstract available
Keywords
CLINICAL TRIALS
COTRANSPORTADORES DE SODIO-GLUCOSA
DAPAGLIFLOZIN
DAPAGLIFLOZINA
DIABETES TIPO 2
EFFICACY
EFICACIA
ESTUDIOS CLÍNICOS
GLUCOSÚRICOS
INHIBIDORES DE SGLT2
SGLT2 INHIBITORS
SAFETY
SEGURIDAD
SODIUM-GLUCOSE CO-TRANSPORTERS
TOLERABILITY
TOLERANCIA
TYPE 2 DIABETES
Cited
Cited by 28 articles
Scroll to top